VYGR stock forecast, quote, news & analysis
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases... Show more
Why Voyager Therapeutics (VYGR) Stock Is Down -36% in the Last 30 Days
Key Takeaways
- Voyager Therapeutics (VYGR) declined roughly 36% over the trailing 30 days, falling from about $2.70 to $1.73.
- The slide reflects sustained technical selling pressure and risk-off conditions across small-cap gene therapy names rather than a single company-specific setback.
- A late-October leadership transition—Robin Swartz appointed President and expected to succeed Alfred Sandrock as CEO—added near-term uncertainty.
- Key Alzheimer's catalysts remain ahead, with VY7523 tau-PET imaging data and VY1706 clinical entry expected in Q4 2026.
- The company ended Q2 2026 with $149 million in cash, which management expects to fund operations into 2028.
- Over the last quarter, shares have fallen about 43%.
- For additional detail, explore Voyager Therapeutics Price Targets, Earnings, and Forecast pages.
- Interested in automated strategies? Explore Tickeron's Trending AI Robots.
Voyager Therapeutics (VYGR) Company Overview and Market Position
Voyager Therapeutics is a clinical-stage biotechnology company focused on genetic medicines for neurological diseases. Its pipeline centers on the TRACER AAV capsid discovery platform, which is designed to generate novel capsids that cross the blood-brain barrier after intravenous dosing. Leading wholly owned programs include VY1706, a tau-silencing gene therapy for Alzheimer's disease, and VY7523, an anti-tau antibody. The company also advances partnered programs in conditions such as Friedreich's ataxia, Huntington's disease, spinal muscular atrophy, ALS, and Parkinson's disease through collaborations with Neurocrine Biosciences, Novartis, and AstraZeneca. Investors follow VYGR for its differentiated CNS delivery technology and for the upcoming clinical readouts that could validate the platform in humans.
Voyager Therapeutics (VYGR) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, VYGR fell from a closing price of $2.70 on September 28, 2026, to $1.73 by late October 2026, a decline of approximately 35.9%. The move was broad-based rather than a single-day event, with shares grinding lower through much of October and briefly touching levels near their 52-week low.
The quarterly trend tells a similar story. About three months earlier, on July 28, 2026, VYGR closed near $3.04; the subsequent slide to $1.73 represents a drop of roughly 43%. This sustained downtrend has left the stock trading well below key moving averages, with momentum indicators remaining in negative territory.
What Drove VYGR Stock Price in the Last 30 Days
The recent decline appears driven primarily by technical and sentiment factors rather than a single negative clinical or financial event. Small-cap gene therapy and biotech names broadly underperformed during the period as elevated Treasury yields and a risk-off market tone weighed on speculative, pre-revenue companies. VYGR, which sits near its 52-week low, saw persistent selling pressure consistent with that sector rotation.
A meaningful company-specific development was the October 21, 2026 announcement of a CEO succession plan. Alfred Sandrock, the company's longtime CEO, is transitioning leadership responsibilities, and Robin Swartz was appointed President effective October 20, 2026, with the expectation that she will become CEO in Q1 2027. Leadership changes ahead of pivotal clinical catalysts can introduce short-term execution uncertainty, and the shares weakened in the days following the announcement.
Also weighing on sentiment is the company's shrinking collaboration revenue, which declined as partnered programs transitioned, alongside a cash balance that has stepped down sequentially from $202 million at the end of 2025 to $149 million at the end of Q2 2026.
What Drove VYGR Stock Performance Over the Last Quarter
The roughly 43% decline over the last three months reflects a broader de-rating of a pre-revenue biotech with no major clinical readouts during the window. With the company's next pivotal Alzheimer's catalysts—VY7523 tau-PET imaging data and VY1706 first-in-human dosing—not expected until Q4 2026, the stock lacked near-term news flow to offset macro-driven selling pressure and a defensive market environment for high-risk, cash-burning issuers.
The quarterly trend was reinforced by investor focus on the company's declining revenue base and rising cash consumption, as collaboration income from partners like Neurocrine and Novartis shifted toward later-stage development with less near-term reimbursement. Despite these pressures, sell-side coverage has remained largely constructive, with multiple analysts reiterating Buy ratings and price targets well above the prevailing share price.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. While Tickeron offers hundreds of automated bots that collectively monitor thousands of tickers, only the top-performing and most relevant strategies appear in this section, giving users a focused view of currently active approaches. The featured bots vary widely in trading style, holding timeframe, and performance metrics, so investors can compare strategies that align with different risk tolerances and objectives. For those seeking a data-driven complement to manual research, the page offers a convenient starting point to explore automated trading tools.
VYGR Stock Forecast Drivers: What Investors Should Watch Next
Several catalysts are likely to shape VYGR's trajectory in the near term. First, the company expects VY7523 tau-PET imaging data from its multiple ascending dose study in Alzheimer's disease during Q4 2026, a readout that could validate or challenge the tau-targeting approach. Second, VY1706 is expected to achieve first-in-human dosing in the second half of 2026, marking clinical entry for the company's tau-silencing gene therapy.
Investors should also monitor the leadership transition as Robin Swartz assumes the CEO role, along with the company's cash runway, which management projects into 2028. Broader considerations include the interest-rate environment, sector sentiment toward pre-revenue biotechs, and any updates from partners such as Neurocrine on the Friedreich's ataxia program. These factors carry significant uncertainty, and outcomes will depend on clinical results and execution rather than on any guaranteed timeline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VYGR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 42 cases where VYGR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VYGR's RSI Indicator exited the oversold zone, 22 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 61 cases where VYGR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for VYGR just turned positive on October 30, 2026. Looking at past instances where VYGR's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +15.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VYGR as a result. In 82 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.744) is normal, around the industry mean (3.498). P/E Ratio (-1.030) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of gene therapies for fatal and debilitating diseases of the central nervous system
Industry Biotechnology